1125 related articles for article (PubMed ID: 26403659)
1. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
2. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
4. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.
Parillaud VR; Lornet G; Monnet Y; Privat AL; Haddad AT; Brochard V; Bekaert A; de Chanville CB; Hirsch EC; Combadière C; Hunot S; Lobsiger CS
J Neuroinflammation; 2017 Mar; 14(1):60. PubMed ID: 28320442
[TBL] [Abstract][Full Text] [Related]
5. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
[TBL] [Abstract][Full Text] [Related]
6. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
7. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
[TBL] [Abstract][Full Text] [Related]
8. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
9. Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.
Annese V; Herrero MT; Di Pentima M; Gomez A; Lombardi L; Ros CM; De Pablos V; Fernandez-Villalba E; De Stefano ME
Brain Struct Funct; 2015 Mar; 220(2):703-27. PubMed ID: 24558048
[TBL] [Abstract][Full Text] [Related]
10. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
11. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
12. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
Stott SRW; Barker RA
Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
[TBL] [Abstract][Full Text] [Related]
13. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
14. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F
J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
16. Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Aguiar AS; Tristão FS; Amar M; Chevarin C; Lanfumey L; Mongeau R; Corti O; Prediger RD; Raisman-Vozari R
Neurotox Res; 2013 Aug; 24(2):280-7. PubMed ID: 23588969
[TBL] [Abstract][Full Text] [Related]
17. Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system.
Ismaiel AA; Espinosa-Oliva AM; Santiago M; García-Quintanilla A; Oliva-Martín MJ; Herrera AJ; Venero JL; de Pablos RM
Toxicol Appl Pharmacol; 2016 May; 298():19-30. PubMed ID: 26971375
[TBL] [Abstract][Full Text] [Related]
18. Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA.
Kuter K; Olech Ł; Głowacka U
Mol Neurobiol; 2018 Apr; 55(4):3049-3066. PubMed ID: 28466266
[TBL] [Abstract][Full Text] [Related]
19. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.
Barnum CJ; Chen X; Chung J; Chang J; Williams M; Grigoryan N; Tesi RJ; Tansey MG
J Parkinsons Dis; 2014; 4(3):349-60. PubMed ID: 25061061
[TBL] [Abstract][Full Text] [Related]
20. Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32β transgenic mice.
Jung YY; Katila N; Neupane S; Shadfar S; Ojha U; Bhurtel S; Srivastav S; Son DJ; Park PH; Yoon DY; Hong JT; Choi DY
Neurochem Int; 2017 Jan; 102():79-88. PubMed ID: 27956238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]